Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
for Hepatocellular Carcinoma
Drug: Rilvegostomig
35 locations incl. Phoenix
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06921785·Phase 3·Recruiting